SCHEMBL26317632

SCHEMBL26317632

O=C(CCc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O)NCCOCCNC(=O)CCc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 8/20 0.59
CSNK1A1 P48729 3/20 0.59
IKZF1 Q13422 2/20 0.59
STAT3 P40763 1/20 0.55
IKZF3 Q9UKT9 5/20 0.53
TNF P01375 5/20 0.53
DDB1 Q16531 2/20 0.53
IL1B P01584 2/20 0.53
BRD4 O60885 1/20 0.53
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
MAP1LC3B Q9GZQ8 2/20 0.45
GSPT1 P15170 2/20 0.45
SALL4 Q9UJQ4 2/20 0.45
HDAC6 Q9UBN7 1/20 0.45
DYRK2 Q92630 1/20 0.44
AXL P30530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30080346 1.00 CRBN (0.59) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL30080325 0.99 CRBN (0.59) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL26323795 0.99 CRBN (0.59) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL26317635 0.99 CRBN (0.59) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL30080490 0.99 CRBN (0.59) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL26317540 0.94 CRBN (0.53) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL21069950 0.89 CRBN (0.59) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL22609531 0.88 CRBN (0.58) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL21855369 0.88 CRBN (0.58) CRBNCSNK1A1IKZF1STAT3IKZF3
SCHEMBL20573534 0.86 CRBN (0.56) CRBNCSNK1A1IKZF1STAT3IKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms CRBN, CD4, CD74 CRBN 1/4885CSNK1A1 2311/4885IKZF1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.